Associated Papers
Oligoprotein type I interferon signatures, but not TREX1 variants, increase risk of systemic lupus erythematosus in UK Biobank.
Rioux B et al.
Nature Communications, 2026
41593088 (PubMed )
Supplement: 41467_2025_67832_MOESM1_ESM.pdf
TREX1 exonuclease in immunity and disease.
Shang Z et al.
International Immunology, 2025
Prevalence and impact of molecular variation in the three-prime repair exonuclease 1 TREX1 and its implications for oncology.
Shekfeh M et al.
Human Genomics, 2025
40581636 (PubMed )
Supplement: 40246_2025_785_MOESM11_ESM.xlsx › Table_S8
Aicardi-Goutières Syndrome with Congenital Glaucoma Caused by Novel TREX1 Mutation.
Świerczyńska M et al.
Journal of Personalized Medicine, 2023
p53 engages the cGAS/STING cytosolic DNA sensing pathway for tumor suppression.
Ghosh M et al.
Molecular Cell, 2023
Structural basis of human TREX1 DNA degradation and autoimmune disease.
Zhou W et al.
Nature Communications, 2022
Human disease phenotypes associated with mutations in TREX1.
Rice GI et al.
Journal of Clinical Immunology, 2015
Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1.
Crow YJ et al.
American Journal of Medical Genetics. Part A, 2015
25604658 (PubMed )
Supplement: supplement_1.docx
The TREX1 C-terminal region controls cellular localization through ubiquitination.
Orebaugh CD et al.
The Journal of Biological Chemistry, 2013
Select a paper to view details